Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
Nidal Muvarak(University of Maryland, Baltimore), Feyruz V. Rassool(University of Maryland, Baltimore), Zeba N. Singh(University of Maryland, Baltimore), Pratik Nagaria(University of Maryland, Baltimore), Limin Xia(National Clinical Research Center for Digestive Diseases), Tyler Rutherford(Stevenson University), Maria R. Baer(University of Maryland, Baltimore), Stephen B. Baylin(Johns Hopkins University), Rena G. Lapidus(University of Maryland, Baltimore), Ying Zou(Lanzhou University), Yi Cai(Johns Hopkins University), Khadiza Chowdhury(University of Maryland, Baltimore), Marina A. Bellani(National Institute on Aging), Søren M. Bentzen(University of Wisconsin–Madison), Michael M. Seidman(National Institutes of Health), Carine Robert(University of Maryland, Baltimore), Eun Yong Choi(University of Maryland, Baltimore), Vu H. Duong(University of Maryland, Baltimore)
Cited by 211
Related Papers
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Epigenetic Determinants of Cancer
|Cold Spring Harbor Perspectives in Biology|2016|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k